Citadel Advisors LLC Takes Position in Novus Therapeutics Inc (NASDAQ:NVUS)

Citadel Advisors LLC acquired a new stake in Novus Therapeutics Inc (NASDAQ:NVUS) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 39,647 shares of the biopharmaceutical company’s stock, valued at approximately $40,000.

Several other institutional investors have also recently made changes to their positions in NVUS. National Asset Management Inc. lifted its holdings in shares of Novus Therapeutics by 69.1% in the second quarter. National Asset Management Inc. now owns 270,000 shares of the biopharmaceutical company’s stock valued at $273,000 after buying an additional 110,295 shares during the period. BlackRock Inc. lifted its holdings in shares of Novus Therapeutics by 69.2% in the second quarter. BlackRock Inc. now owns 33,544 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 13,721 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in shares of Novus Therapeutics by 528.2% in the second quarter. Vanguard Group Inc. now owns 270,160 shares of the biopharmaceutical company’s stock valued at $273,000 after buying an additional 227,157 shares during the period. Institutional investors and hedge funds own 45.29% of the company’s stock.

Several analysts have recently weighed in on the company. LADENBURG THALM/SH SH restated a “buy” rating and issued a $10.00 price objective on shares of Novus Therapeutics in a report on Monday, August 19th. ValuEngine lowered Novus Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, September 4th. Finally, Zacks Investment Research raised Novus Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a research report on Friday, August 23rd.

Shares of Novus Therapeutics stock opened at $0.54 on Friday. The stock’s fifty day moving average is $0.69 and its 200-day moving average is $1.66. The firm has a market capitalization of $7.01 million, a PE ratio of -0.35 and a beta of 2.86. The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 0.01. Novus Therapeutics Inc has a 12-month low of $0.50 and a 12-month high of $5.21.

Novus Therapeutics (NASDAQ:NVUS) last announced its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.35). Analysts expect that Novus Therapeutics Inc will post -1.5 EPS for the current year.

Novus Therapeutics Company Profile

Novus Therapeutics, Inc, a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection).

Further Reading: Bear Market – How and Why They Occur

Want to see what other hedge funds are holding NVUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novus Therapeutics Inc (NASDAQ:NVUS).

Institutional Ownership by Quarter for Novus Therapeutics (NASDAQ:NVUS)

Receive News & Ratings for Novus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.